KYMERA THERAPEUTICS, INC. Contract with Customer, Receivable, after Allowance for Credit Loss
KYMERA THERAPEUTICS, INC. (KYMR) had Contract with Customer, Receivable, after Allowance for Credit Loss of $20.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Revenue from Contract with Customer
us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Receivable, after Allowance for Credit Loss $20.00M.
- 2025-12-31: Contract with Customer, Receivable, after Allowance for Credit Loss $0.00.
- 2025-09-30: Contract with Customer, Receivable, after Allowance for Credit Loss $0.00.
- 2025-06-30: Contract with Customer, Receivable, after Allowance for Credit Loss $40.00M.
| Period end | Contract with Customer, Receivable, after Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $20.00M 10-Q · filed 2026-08-05 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-05 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 |
| 2025-06-30 | $40.00M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $20.00M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $947.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.32M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $1.70M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $2.03M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $18.76M 10-K · filed 2025-02-27 |
| 2023-09-30 | $3.78M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $4.12M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $3.32M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $2.54M 10-K · filed 2024-02-22 |
| 2022-09-30 | $2.88M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $2.37M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.26M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $135.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $1.57M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $904.00K 10-Q · filed 2021-08-06 |
| 2021-03-31 | $1.73M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $1.43M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |